【环球网财经综合报道】历经四年连跌，医药板块今年迎来回暖迹象。Wind数据显示，截至5月16日，超八成医药相关主 题基金上涨，11只产品涨幅超30%，长城医药产业精选A以42.48%年内回报领跑，业绩首尾差距超53个百分点。 对于创新药崛起原因，业内人士认为，受益于政策支持、集采规则优化及头部药企研发进展加速，随着国产创新药出海及 国内外商业化推进，板块未来可期。长城基金梁福睿表示，今年创新药板块有业绩支撑，数据和BD兑现力度强，未来股价 走势或好于过去，中国创新药行业发展才刚开始。 此外，业内人士对比A股和港股市场指出，港股创新药企业估值泡沫少、优质资产多、板块Beta强；A股有较多由仿制药转 型创新药企业，后续估值上升空间或更大。同时，AI医疗方向也成为机构投资者关注焦点，单林认为创新药是中期高胜率 资产，AI医疗是较好赔率型资产机会，AI加持为医药板块带来新变量。（陈十一） 业绩分化背后，港股创新药表现亮眼，港股通创新药指数年内上涨28.37%，重仓与否成医药主题产品业绩"胜负手"。业绩 排名前列的医药主题基金大多重仓港股创新药标的，如长城医药产业精选A一季度末含"港"量35.2%，前十大重仓股半数为 ...

Group 1 - The Hong Kong stock market experienced a collective rise, with the Hang Seng Index up by 0.74% and the Hang Seng Tech Index up by 0.8% [1] - The Hong Kong Innovative Drug ETF (159567) increased by 1.71%, with a turnover rate of 6.72% and a trading volume exceeding 115 million yuan, indicating active trading [1] - Key stocks in the ETF saw significant gains, with Junshi Biosciences rising over 9%, CanSino Biologics up over 8%, and Kelun Pharmaceutical increasing over 7% [1] Group 2 - Industry analysts believe that the innovative drug sector's growth is sustainable, driven by a combination of innovation and internationalization, supported by policies and increasing global competitiveness [1] - The innovative drug sector is expected to be a key investment theme for the pharmaceutical sector in 2025, with signs of recovery in domestic demand and improvements in the medical device sector [2] - AI in healthcare is anticipated to bring new changes to the pharmaceutical industry, highlighting the importance of this trend [1]

Core Viewpoint - Alibaba Health reported strong financial results for the fiscal year 2025, marking the third consecutive year of revenue and net profit growth, driven by increased user engagement and innovation in its business model [1][2][4]. Financial Performance - For the fiscal year 2025, Alibaba Health achieved a revenue of 30.598 billion yuan, representing a year-on-year growth of 13.2% [2]. - The net profit for the same period was 1.432 billion yuan, showing a significant increase of 62.2% year-on-year [2]. - Adjusted net profit reached 1.95 billion yuan, up 35.6% compared to the previous year [1][2]. Historical Performance - Alibaba Health's revenue has shown a consistent upward trend, increasing from 9.596 billion yuan in fiscal year 2020 to 30.598 billion yuan in fiscal year 2025 [3]. - The net profit has fluctuated but generally trended upwards, from a loss of 6.586 million yuan in fiscal year 2020 to a profit of 1.432 billion yuan in fiscal year 2025 [3]. Business Development - The company has enhanced its one-stop healthcare service capabilities, focusing on improving user experience through better product offerings and services [4]. - The Tmall Health platform has seen steady growth, with a significant increase in annual GMV and active users, and the number of online products grew by over 91% to 133 million [4]. Investment in Innovation - Alibaba Health invested 720 million yuan in product development during fiscal year 2025, focusing on AI technology, business optimization, and digital traceability [5]. - The company’s self-operated pharmaceutical business generated over 26.124 billion yuan in revenue, reflecting a year-on-year growth of 10% [5]. Market Position and Stock Performance - Alibaba Health's stock price saw a cumulative increase of over 60% in February and March due to the recovery of the Hong Kong tech sector and interest in AI healthcare concepts, but has since declined [7]. - As of May 20, the stock price was 4.89 HKD per share, with a total market capitalization of 78.7 billion HKD [7].

Group 1 - The Hong Kong stock market for healthcare opened high and showed strong performance, particularly in innovative drugs and medical devices sectors, with the Hang Seng Healthcare Index ETF (159557) rising by 4.02% [1] - Notable stocks included in the ETF saw significant gains, with 3SBio rising over 35%, and other companies like Innovent Biologics, CSPC Pharmaceutical Group, and Ascentage Pharma also experiencing upward movement [1] - 3SBio announced a licensing agreement with its affiliate 3SBio and Shenyang 3SBio for exclusive global development, production, and commercialization of a product related to Pfizer's 707 project [1] Group 2 - Jianghai Securities highlighted that the acceleration of medical device approvals in China is expected to improve the profit outlook and valuation recovery for medical device export companies [2] - The easing of cost pressures and an improved market environment will release profit margins, with low-value consumables and mid-range equipment sectors being the first to benefit [2] - Long-term, the global competition in medical devices is shifting towards technological breakthroughs and supply chain restructuring, necessitating China to overcome "technical bottlenecks" in high-end imaging equipment and surgical robots [2] Group 3 - Policy incentives and independent innovation will be crucial for companies to break through in the market, with leading firms likely to explore AI healthcare and surgical robots to overcome overseas technological barriers [2] - Investment recommendations suggest focusing on leading companies with strong technological barriers and high elasticity in export-oriented businesses to capitalize on profit growth and valuation recovery during the policy window [2] - According to CMB International, the Chinese pharmaceutical industry is expected to continue its valuation recovery by 2025, driven by positive factors such as the success of innovative drugs abroad, adjustments in medical insurance catalogs, and the revival of medical device tenders [2]

【机构调研】这家营养素供应商一季度 业绩超预期，资产重组有望完善底层研 发实力 2025-05-19 19:55:43 调研要点 : ①这家微生物合成营养素供应商切入"宠物营养+美 妆个护"两大领域,公司涵盖全线宠物食品品类, 储备麦角硫因等多款功能性原料，定增并购事项已 获上交所受理; ②风险提示：调研内容仅为机构与上市公司间的业 务交流，不构成投研观点，信息以上市公司公告和 分析师公开报告为准。 嘉必优于5月6日至5月16日期间接待多批机构调 研,随着新国标对婴配粉生产研发能力、配方科学 性等方面提出了更严格的标准，将加速促使婴幼儿 奶粉市场向具备技术优势和产品优势的头部企业集 中，婴配奶粉企业的集中度进一步提升。 公司深耕婴配领域，长期与飞鹤、伊利、雀巢、达 能、嘉吉、等国内外知名企业头部客户保持稳定深 入的合作，随着行业集中度上升及客户的成长，公 司产品的市场份额稳步提升。 宠物营养领域，基于脂肪酸平衡理论，公司针对不 同生命阶段的宠物健康问题，开展了系列产品应用 解决方案设计和研发。公司动物营养事业部与参股 公司全硕全面合作，已涵盖宠物营养主食、营养补 充剂、营养零食等全线宠物食品品类。 美妆个护是 ...

策 略 研 究 医疗与消费周报——AI 医疗：AI 医疗海外增长 迅猛，渗透率或打开空间 投资要点： 近期观点 1、医药指数本周关注的 6 个子行业全部录得正收益，表现良好。 策 略 定 期 报 告 2、美国 AI 医疗企业业绩和股价集体走强，AI 大模型公司加速布 局医疗领域。根据动脉智库《医疗大模型研究报告》，医疗大模型市 场规模 2019 年至 2023 年期间年均复合增长率超 100%，预计 2028 年 达 111.6 亿元。根据沙利文与头豹研究院《2024 年中国医疗大健康产 业发展白皮书》以及亿欧智库的测算，目前医疗大模型渗透率低，但 2030 年有望超过 40%。安全性、有效性验证和监管体系缺乏是商业化 推广的主要限制因素。 团队成员 分析师： 赵月(S0210524050016) zy30563@hfzq.com.cn 相关报告 1、如何看指数冲高回落？——2025.05.18 2、市场状态高频数据库——5 月第 3 周—— 2025.05.18 3、重视核心资产风格——产业经济周观点—— 2025.05.18 风险提示 2025 年 05 月 19 日 技术研发不及预期；宏观需求变化；地缘 ...

2025.05. 19 本文字数：2606，阅读时长大约5分钟 作者 | 第一财经 曹璐 今年以来，历经四年连跌的医药板块似乎迎来一波曙光，不少医药主题基金净值回暖明显。Wind数 据显示，截至5月16日，超八成医药相关主题基金上涨，11只产品涨幅超30%，其中长城医药产业精 选A以42.48%的年内回报领跑，这类产品的业绩首尾差距已经超过53个百分点。 业 绩 分 化 背 后 ， 港 股 创 新 药 的 强 势 表 现 尤 为 瞩 目 ， 相 关 指 数 （ 港 股 通 创 新 药 指 数 ） 年 内 上 涨 28.37%，重仓与否也成为医药主题产品的业绩"胜负手"。那么，港股创新药为何会有如此亮眼的表 现，这是否意味着医药赛道已经重新崛起？ "创新药是大类科技资产里基本面相对扎实的品种，预计今年其股价走势有望比过去几年更加顺 畅。"长城基金基金经理梁福睿对第一财经表示，创新药这波强势行情的底层逻辑在于，科技资产牛 的背景下，创新药产业的逻辑在不断强化。 交银医疗健康基金经理徐嘉辰则认为，创新药年初以来的行情不是偶然，也不完全是科技创新风格的 外溢，而是中国创新企业的国际竞争力明显提升，伴随的是整个中国创新 ...

Group 1 - The Hong Kong stock market opened lower on May 19, with the Hang Seng Index down 0.73% and the Hang Seng Tech Index down 1.58% [1] - The Hong Kong Innovative Drug ETF (159567) rose by 0.58% with a turnover rate of 8.02% and a trading volume exceeding 1.15 billion yuan, indicating active trading [1] - The innovative drug ETF closely tracks the Hong Kong Stock Connect Innovative Drug Index, reflecting the performance characteristics of biotech companies listed in Hong Kong [1] Group 2 - The pharmaceutical sector has shown a strong rebound this year, with several pharmaceutical funds reporting net value increases exceeding 30% [1] - Institutions are focusing on investment opportunities in AI healthcare, brain-computer interfaces, and innovative drugs following a period of deep adjustment in the pharmaceutical sector [1] - Guojin Securities emphasizes that innovative drugs and certain semi-innovative drugs remain key investment areas, with upcoming policy changes and data releases expected to catalyze stock price movements [1] Group 3 - Guoxin Securities highlights the rapid growth phase of the innovative drug sector, driven by commercialization and external licensing, which is accelerating revenue growth and profitability [2] - The traditional Chinese medicine sector faces short-term pressure but retains long-term branding and innovation potential [2] - The medical device sector is under short-term pressure due to slow policy implementation and inventory issues, but there are expectations for recovery driven by improved bidding processes [2]

证券研究报告 医药生物 行业定期报告 hyzqdatemark 2025 年 05 月 19 日 板块表现： 长春高新，涅槃重生？ 投资评级： 看好（维持） ——医药行业周报（25/5/12-25/5/16） 投资要点： 请务必仔细阅读正文之后的评级说明和重要声明 证券分析师 本周医药市场表现分析：5 月 12 日至 5 月 16 日，医药指数上涨 1.27%，相对沪深 300 指数 超额收益为+0.16%。本周题材性个股表现较好，拓新药业、川宁生物、华大基因等。建议关 注：1）创新药作为产业趋势，近期盘整较为充分，继续重点推荐 A 股信立泰、科伦药业、热 景生物、一品红、科兴制药、恒瑞医药；港股三生制药、科伦博泰、康方生物、中国生物制 药；2）业绩落地、估值较低的个股，建议关注长春高新（创新药）、昆药集团、开立医疗、 迈瑞医疗、鱼跃医疗、海泰新光等；3）Ai/科技+医疗，建议关注华大智造、麦澜德、三友医 疗、润达医疗、塞力医疗、乐心医疗等。 联系人 医药指数和各细分领域表现、涨跌幅：本周医药指数上涨 1.27%，上涨个股数量 345 家，下 跌个股 138 家，涨幅居前为拓新药业（+45.03%）、永安药业 ...

自2019年至2020年走出一轮强势行情以来，医药板块回调已有将近五年时间。今年以来，在创新药概念 的带动下，医药板块投资逐渐回暖。近日，融通健康产业基金经理万民远在接受中国证券报记者专访时 表示，无论是从政策端、需求端还是企业创新端来看，医药行业最困难的时刻或许已经过去，该行业的 投资筹码出清已经较为彻底，当下其对医药行情的预期相对乐观。 作为有着医学专业背景的基金经理，万民远最早从四川大学华西医学院遗传学博士毕业，曾在券商研究 所、公私募基金工作，金融从业时间超14年。目前，逆向投资已成为他坚定的选择，"在买入后下跌空 间很小，在估值泡沫时逐步卖出"是他投资决策的核心目标。他坦言，这种方式确实有些逆人性，但起 码可以让投资处在相对安全的范围内。比起追求上涨空间，他更注重投资的安全性。 买在无人问津处 "我个人的风险偏好比较低。"万民远直言，他在选股时会更偏好左侧投资，耐心等待拐点的到来。虽然 大家都想等到反转出现时再买入，但当基本面真正明显起来的时候，可能股价已经涨得差不多了。因 此，投资需要一些前瞻性，否则很容易错过。而当市场过热，估值出现泡沫时，他就会选择卖出。在他 看来，或许当所有人蜂拥而入时，股价 ...